Eflornithine plus Sulindac

Phase 3Small molecule

CCancer Prevention Pharmaceuticals, Inc.

Eflornithine plus Sulindac is one of 13 small molecule programs targeting Adenoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenomaActive, not recruiting

AdenomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Adenoma

#DrugCompanyPhaseTrials

Dostinex

Pfizer

Approved

4 2

Orilissa

AbbVie

Approved

1 3

Nolvadex

Duragesic

Eflornithine plus Sulindac

CCancer Prevention Pharmaceuticals, Inc.

Phase 3

1 6

Biaxin

AbbVie

Preclinical

1 7

Avandia

Jazz Pharmaceuticals

Preclinical

1 8

Ultram

WWim Janssens

Preclinical

1 9

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Drug Treatment

BBiosense Webster, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 3Active, not recruiting

Adenoma

NCT01349881

Clinical

Trials by Indication[1]

Familial adenomatous polyposis1 trial

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

Withdrawn·CCancer Prevention Pharmaceuticals, Inc.·Phase 3·NCT01245816

Adenoma1 trial

S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting·SSWOG Cancer Research Network·Phase 3·NCT01349881·354 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Eflornithine plus Sulindac. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eflornithine plus Sulindac compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eflornithine plus Sulindac. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cancer Prevention Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCancer Prevention Pharmaceuticals, Inc.

Eflornithine plus Sulindac

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Familial adenomatous polyposis1 trial

Adenoma1 trial

References

Drug Info

Quick Facts

Related News